Glucose-induced LINC01419 reprograms the glycolytic pathway by recruiting YBX1 to enhance PDK1 mRNA stability in hepatocellular carcinoma

Abstract

	•This study highlights the considerable regulatory role of LINC01419 in the metabolism of HCC.
	•The newly identified LINC01419/YBX1-PDK1 axis constitutes a valuable target.
	•Hepatic-specific delivery of GalNAc-siLINC01419 presents a promising therapeutic strategy for HCC.

Keywords

glycolytic pathway / hepatocellular carcinoma / LINC01419 / mRNA stability / PDK1

References

[1] Martinez-ReyesI, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021; 21(10): 669-680.

[2] FaubertB, Solmonson A, DeBerardinisRJ. Metabolic reprogramming and cancer progression. Science. 2020; 368(6487).

[3] LiF, SimonMC. Cancer cells don’t live alone: metabolic communication within tumor microenvironments. Dev Cell. 2020; 54(2): 183-195.

[4] ZhangQ, LouY, YangJ, et al. Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas. Gut. 2019; 68(11): 2019-2031.

[5] TohMR, WongEYT, WongSH, et al. Global epidemiology and genetics of hepatocellular carcinoma. Gastroenterology. 2023; 164(5): 766-782.

[6] HayN. Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?. Nat Rev Cancer. 2016; 16(10): 635-649.

[7] Vander HeidenMG, Cantley LC, ThompsonCB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324(5930): 1029-1033.

[8] QiaoQ, HuS, WangX. The regulatory roles and clinical significance of glycolysis in tumor. Cancer Commun (Lond). 2024.

[9] LibertiMV, DaiZ, WardellSE, et al. A predictive model for selective targeting of the Warburg effect through GAPDH inhibition with a natural product. Cell Metab. 2017; 26(4): 648-659.

[10] ShanW, ZhouY, TamKY. The development of small-molecule inhibitors targeting hexokinase 2. Drug Discov Today. 2022; 27(9): 2574-2585.

[11] XuS, Herschman HR. A tumor agnostic therapeutic strategy for hexokinase 1-null/hexokinase 2-positive cancers. Cancer Res. 2019; 79(23): 5907-5914.

[12] KimJW, Tchernyshyov I, SemenzaGL, DangCV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006; 3(3): 177-185.

[13] McFateT, Mohyeldin A, LuH, et al. Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem. 2008; 283(33): 22700-22708.

[14] DupuyF, Tabaries S, AndrzejewskiS, et al. PDK1-dependent metabolic reprogramming dictates metastatic potential in breast cancer. Cell Metab. 2015; 22(4): 577-589.

[15] ZhangM, CongQ, ZhangXY, Zhang MX, LuYY, XuCJ. Pyruvate dehydrogenase kinase 1 contributes to cisplatin resistance of ovarian cancer through EGFR activation. J Cell Physiol. 2019; 234(5): 6361-6370.

[16] WangQ, LiangN, LiuC, et al. BEX1 supports the stemness of hepatoblastoma by facilitating Warburg effect in a PPARgamma/PDK1 dependent manner. Br J Cancer. 2023; 129(9): 1477-1489.

[17] ZuoQ, HeJ, ZhangS, et al. PPARgamma coactivator-1alpha suppresses metastasis of hepatocellular carcinoma by inhibiting warburg effect by PPARgamma-dependent WNT/beta-catenin/pyruvate dehydrogenase kinase isozyme 1 axis. Hepatology. 2021; 73(2): 644-660.

[18] AnwarS, ShamsiA, MohammadT, Islam A, HassanMI. Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy. Biochim Biophys Acta Rev Cancer. 2021; 1876(1): 188568.

[19] TataranniT, Piccoli C. Dichloroacetate (DCA) and cancer: an overview towards clinical applications. Oxid Med Cell Longev. 2019; 2019: 8201079.

[20] StatelloL, GuoCJ, ChenLL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021; 22(2): 96-118.

[21] TanYT, LinJF, LiT, LiJJ, XuRH, JuHQ. LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer. Cancer Communications. 2020; 41(2): 109-120.

[22] LiuJ, LiuZX, WuQN, et al. Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. Nat Commun. 2020; 11(1): 1507.

[23] YuT, ZhaoY, HuZ, et al. MetaLnc9 facilitates lung cancer metastasis via a PGK1-activated AKT/mTOR pathway. Cancer Res. 2017; 77(21): 5782-5794.

[24] BianZ, ZhangJ, LiM, et al. LncRNA-FEZF1-AS1 promotes tumor proliferation and metastasis in colorectal cancer by regulating PKM2 signaling. Clin Cancer Res. 2018; 24(19): 4808-4819.

[25] WangC, LiY, YanS, et al. Interactome analysis reveals that lncRNA HULC promotes aerobic glycolysis through LDHA and PKM2. Nat Commun. 2020; 11(1): 3162.

[26] LinA, LiC, XingZ, et al. The LINK-A lncRNA activates normoxic HIF1alpha signalling in triple-negative breast cancer. Nat Cell Biol. 2016; 18(2): 213-224.

[27] ChenF, ChenJ, YangL, et al. Extracellular vesicle-packaged HIF-1alpha-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells. Nat Cell Biol. 2019; 21(4): 498-510.

[28] TangJ, YanT, BaoY, et al. LncRNA GLCC1 promotes colorectal carcinogenesis and glucose metabolism by stabilizing c-Myc. Nat Commun. 2019; 10(1): 3499.

[29] SahaS, KiranM, KuscuC, et al. Long noncoding RNA DRAIC inhibits prostate cancer progression by interacting with IKK to inhibit NF-kappaB activation. Cancer Res. 2020; 80(5): 950-963.

[30] LyabinDN, Eliseeva IA, OvchinnikovLP. YB-1 protein: functions and regulation. Wiley Interdiscip Rev RNA. 2014; 5(1): 95-110.

[31] KosnopfelC, Sinnberg T, SauerB, et al. YB-1 expression and phosphorylation regulate tumorigenicity and invasiveness in melanoma by influencing EMT. Mol Cancer Res. 2018; 16(7): 1149-1160.

[32] LiH, ZhangD, FuQ, et al. YBX1 as an oncogenic factor in T-cell acute lymphoblastic leukemia. Blood Adv. 2023; 7(17): 4874-4885.

[33] PernerF, Schnoeder TM, XiongY, et al. YBX1 mediates translation of oncogenic transcripts to control cell competition in AML. Leukemia. 2022; 36(2): 426-437.

[34] ZhengC, WeiY, ZhangQ, et al. Multiomics analyses reveal DARS1-AS1/YBX1-controlled posttranscriptional circuits promoting glioblastoma tumorigenesis/radioresistance. Sci Adv. 2023; 9(31): eadf3984.

[35] LiaoLZ, ChenCT, LiNC, et al. Y-Box binding protein-1 promotes epithelial-mesenchymal transition in sorafenib-resistant hepatocellular carcinoma cells. Int J Mol Sci. 2020; 22(1).

[36] LiuB, ShenH, HeJ, et al. Cytoskeleton remodeling mediated by circRNA-YBX1 phase separation suppresses the metastasis of liver cancer. Proc Natl Acad Sci U S A. 2023; 120(30): e2220296120.

[37] YuT, ZhangQ, YuSK, et al. THOC3 interacts with YBX1 to promote lung squamous cell carcinoma progression through PFKFB4 mRNA modification. Cell Death Dis. 2023; 14(7): 475.

[38] GandhiM, GrossM, HollerJM, et al. The lncRNA lincNMR regulates nucleotide metabolism via a YBX1 -RRM2 axis in cancer. Nat Commun. 2020; 11(1): 3214.

[39] DangH, ChenL, TangP, et al. LINC01419 promotes cell proliferation and metastasis in hepatocellular carcinoma by enhancing NDRG1 promoter activity. Cell Oncol (Dordr). 2020; 43(5): 931-947.

[40] LiZ, ZhangH, LiQ, et al. GepLiver: an integrative liver expression atlas spanning developmental stages and liver disease phases. Sci Data. 2023; 10(1): 376.

[41] DengB, XuW, WangZ, et al. An LTR retrotransposon-derived lncRNA interacts with RNF169 to promote homologous recombination. EMBO Rep. 2019; 20(11): e47650.

[42] HouY, ChenK, LiaoR, Li Y, YangH, GongJ. LINC01419-mediated epigenetic silencing of ZIC1 promotes metastasis in hepatocellular carcinoma through the PI3K/Akt signaling pathway. Lab Invest. 2021; 101(5): 570-587.

[43] ChenX, LiA, SunBF, et al. 5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs. Nat Cell Biol. 2019; 21(8): 978-990.

[44] XuJ, JiL, LiangY, et al. CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1. Signal Transduct Target Ther. 2020; 5(1): 298.

[45] FengM, XieX, HanG, et al. YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner. Blood. 2021; 138(1): 71-85.

[46] HentzeMW, Castello A, SchwarzlT, PreissT. A brave new world of RNA-binding proteins. Nat Rev Mol Cell Biol. 2018; 19(5): 327-341.

[47] SunW, XieZ, LiuY, et al. JX06 selectively inhibits pyruvate dehydrogenase kinase PDK1 by a covalent cysteine modification. Cancer Res. 2015; 75(22): 4923-4936.

[48] StacpoolePW. therapeutic targeting of the pyruvate dehydrogenase complex/pyruvate dehydrogenase kinase (PDC/PDK) axis in cancer. J Natl Cancer Inst. 2017; 109(11).

[49] SchoenmannN, Tannenbaum N, HodgemanRM, RajuRP. Regulating mitochondrial metabolism by targeting pyruvate dehydrogenase with dichloroacetate, a metabolic messenger. Biochim Biophys Acta Mol Basis Dis. 2023; 1869(7): 166769.

[50] ShenYC, OuDL, HsuC, et al. Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma. Br J Cancer. 2013; 108(1): 72-81.

[51] WeintraubAS, LiCH, ZamudioAV, et al. YY1 is a structural regulator of enhancer-promoter loops. Cell. 2017; 171(7): 1573-1588.

[52] MelialaITS, HoseaR, KasimV, Wu S. The biological implications of Yin Yang 1 in the hallmarks of cancer. Theranostics. 2020; 10(9): 4183-4200.

[53] SantiagoFS, IshiiH, ShafiS, et al. Yin Yang-1 inhibits vascular smooth muscle cell growth and intimal thickening by repressing p21WAF1/Cip1 transcription and p21WAF1/Cip1-Cdk4-cyclin D1 assembly. Circ Res. 2007; 101(2): 146-155.

[54] SchwaliePC, WardMC, CainCE, et al. Co-binding by YY1 identifies the transcriptionally active, highly conserved set of CTCF-bound regions in primate genomes. Genome Biol. 2013; 14(12): R148.

[55] LeeNCW, Carella MA, PapaS, BubiciC. High expression of glycolytic genes in cirrhosis correlates with the risk of developing liver cancer. Front Cell Dev Biol. 2018; 6: 138.

[56] LuoX, HeX, ZhangX, et al. Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy. MedComm (2020). 2024; 5(2): e474.

[57] HuangA, YangX-R, ChungW-Y, Dennison AR, ZhouJ. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020; 5(1).

[58] HanahanD, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5): 646-674.

[59] DeBerardinisRJ, LumJJ, HatzivassiliouG, ThompsonCB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008; 7(1): 11-20.

[60] HolnessMJ, SugdenMC. Regulation of pyruvate dehydrogenase complex activity by reversible phosphorylation. Biochem Soc Trans. 2003; 31(6): 1143-1151.

[61] HirschhaeuserF, Sattler UG, Mueller-KlieserW. Lactate: a metabolic key player in cancer. Cancer Res. 2011; 71(22): 6921-6925.

[62] MordovkinaD, LyabinDN, SmolinEA, Sogorina EM, OvchinnikovLP, EliseevaI. Y-Box binding proteins in mRNP assembly, translation, and stability control. Biomolecules. 2020; 10(4).

[63] ShenH, YingY, MaX, et al. FTO promotes clear cell renal cell carcinoma progression via upregulation of PDK1 through an m(6)A dependent pathway. Cell Death Discov. 2022; 8(1): 356.

[64] TianJ, GaoJ, ChengC, et al. NOP2-mediated 5-methylcytosine modification of APOL1 messenger RNA activates PI3K-Akt and facilitates clear cell renal cell carcinoma progression. Int J Biol Sci. 2024; 20(12): 4853-4871.

[65] XueC, GuX, ZhengQ, et al. ALYREF mediates RNA m(5)C modification to promote hepatocellular carcinoma progression. Signal Transduct Target Ther. 2023; 8(1): 130.

[66] ShaathH, Vishnubalaji R, ElangoR, et al. Long non-coding RNA and RNA-binding protein interactions in cancer: experimental and machine learning approaches. Semin Cancer Biol. 2022; 86(3): 325-345.

[67] LiW, DengX, ChenJ. RNA-binding proteins in regulating mRNA stability and translation: roles and mechanisms in cancer. Semin Cancer Biol. 2022; 86(2): 664-677.

[68] YangT, ShuF, YangH, et al. YY1: a novel therapeutic target for diabetic nephropathy orchestrated renal fibrosis. Metabolism. 2019; 96: 33-45.

[69] HiromuraM, ChoiCH, SabourinNA, Jones H, BachvarovD, UshevaA. YY1 is regulated by O-linked N-acetylglucosaminylation (O-glcNAcylation). J Biol Chem. 2003; 278(16): 14046-14052.

[70] NanY, LuoQ, WuX, et al. DLGAP1-AS2-mediated phosphatidic acid synthesis activates YAP signaling and confers chemoresistance in squamous cell carcinoma. Cancer Res. 2022; 82(16): 2887-2903.

[71] MengM, YangL, ZhouH, et al. LINC00978 regulates metabolic rewiring to promote the malignancy of glioblastoma through AKR1B1. Cancer Lett. 2023; 567: 216277.

[72] SchmidtK, Prakash TP, DonnerAJ, et al. Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor. Nucleic Acids Res. 2017; 45(5): 2294-2306.

[73] StineZE, SchugZT, SalvinoJM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov. 2022; 21(2): 141-162.

[74] SwantonC, Bernard E, AbboshC, et al. Embracing cancer complexity: hallmarks of systemic disease. Cell. 2024; 187(7): 1589-1616.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.